Sec. 2. Requiring parity in cost-sharing and treatment limitations with respect to diagnostic and screening examinations for breast cancer
471 words·~2 min read·
/bill/116/s/3216/is/section-2A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
Section 2719A of the Public Health Service Act ( 42 U.S.C. 300gg–19a ) is amended by adding at the end the following new subsection: In the case of a group health plan, or a health insurance issuer offering group or individual health insurance coverage, that provides benefits with respect to a diagnostic examination for breast cancer furnished to an individual enrolled under such plan or such coverage, such plan or such coverage shall ensure that— the cost-sharing requirements applicable to such examination for such individual are no less favorable than such requirements applicable to a screening examination for breast cancer for such individual; and the treatment limitations applicable to such diagnostic examination for breast cancer for such individual are no less favorable than such limitations applicable to a screening examinations for breast cancer for such individual.
A group health plan or health insurance issuer may not, for the sole purpose of complying with paragraph (1), increase cost-sharing requirements with respect to screening examinations for breast cancer. Nothing in this subsection shall be construed— to require the use of diagnostic examinations for breast cancer as a replacement for screening examinations for breast cancer; to prohibit a group health plan or health insurance issuers from requiring prior authorization or imposing other appropriate utilization controls in approving coverage for any screening or diagnostic imaging; or to supersede a State law that provides greater protections with respect to the coverage of diagnostic examinations for breast cancer than is provided under this subsection.
In this subsection: The term cost-sharing requirement includes a deductible, coinsurance, copayment, and any maximum limitation on the application of such a deductible, coinsurance, copayment, or similar out-of-pocket expense. The term diagnostic examination for breast cancer means a medically necessary and appropriate (as determined by the health care professional treating the individual) examination for breast cancer to evaluate an abnormality in the breast that is— seen or suspected from a screening examination for breast cancer; detected by another means of examination; or suspected based on the medical history or family medical history of the individual.
The term examination for breast cancer includes such an examination using breast ultrasound, breast magnetic resonance imaging, or mammography. The term treatment limitation includes limits on the frequency of treatment, number of visits, days of coverage, or other similar limits on the scope or duration of treatment. . Section 1251(a)(4)(A) of the Patient Protection and Affordable Care Act ( 42 U.S.C. 18011(a)(4)(A) ) is amended— by striking title and inserting title, or as added after the date of the enactment of this Act) ; and by adding at the end the following new clause:
Section 2719A(e) (relating to parity for diagnostic and screening examinations for breast cancer). . The amendments made by this section shall apply with respect to plan years beginning on or after January 1, 2021.
Connectionstraces to 1
Traces to 1 document
1 reference not yet in our index
- 42 USC 300gg–19a
Citation graph
cites case law
Sec. 2
Requiring parity in cost-sharing and treatment limitations with respect to diagnostic and screening examinations for breast cancer
Cite42 USC 300gg–19a
Cites 2Cited by 0 across 0 sources